Abstract
Polymeric micelles have attracted considerable attention for effective delivery of poorly water-soluble cancer drugs. Polyethylene glycol (PEG), which has been approved for human use by the US Food and Drug Administration, is the most commonly used hydrophilic component of polymeric micelles because it is biocompatible and biodegradable. One disadvantage of traditional polymeric micelles is that they include a large amount of inert carrier materials, which do not contribute to therapeutic activity but increase cost and toxicity risk. A better alternative may be “dual-functional” micellar carriers, in which the hydrophobic carrier material (conjugated to PEG) has intrinsic therapeutic activity that complements, or even synergizes with, the antitumor activity of the drug cargo. This review summarizes recent progress in the development of PEG-derivatized dual-functional nanomicelles and surveys the evidence of their feasibility and promise for cancer therapy.
Introduction
Cancer has become the “first killer” that threatens human health (Siegel et al., 2017; Smith et al., 2017; Torre et al., 2017). Chemotherapy, one of the most important tools in clinical cancer treatment, inhibits growth of primary tumors and suppresses proliferation of metastatic tumor cells (Chabner and Roberts, 2005). Although many anticancer drugs have been approved, their clinical application is often compromised by poor water solubility, short circulation time, and serious systemic side effects (Shi et al., 2016; Youn and Bae, 2018). Nanomaterials have been widely used in cancer therapy (Wicki et al., 2015). Various nanocarriers, including nanoparticles (Geszke-Moritz and Moritz, 2016), liposomes (Cheng and Ji, 2019), micelles (Cagel et al., 2017), and dendrimers (Ray et al., 2018), have opened up new possibilities for sustained, controlled, and targeted cancer drug delivery, achieving higher effective drug concentrations at the tumor site with fewer off-target side effects. In particular, polymeric micelles have attracted attention as multifunctional drug delivery systems for poorly water-soluble agents (Zhang et al., 2014h; Biswas et al., 2016).
Polymeric micelles are self-assembling nanoparticles (5–200 nm) composed of amphiphilic polymers. The structure of polymeric micelles follows and exemplifies the similar structure of micelles proposed as per different micellar theories (Gothwal et al., 2016). It is composed of a “core,” which is usually a hydrophobic section while the exterior, which is also known as “shell,” represents a hydrophilic block of the copolymer structure (Figure 1) (Mohamed et al., 2014; Zhang et al., 2014d). Polymeric micelles are easy to prepare, highly biocompatible, and quite efficient at encapsulating and delivering drugs in the body (Gong et al., 2012). Polymeric micelles can encapsulate water-insoluble agents in their hydrophobic core, improving bioavailability (Kedar et al., 2010; Tanbour et al., 2016). A hydrophilic shell of polyethylene glycol (PEG) can significantly prolong the circulation time of polymeric micelles in the blood (Suk et al., 2016). Polymeric micelle in the 10–100 nm range can pass through the leaky vasculature and passively accumulate in tumors via the enhanced permeability and retention effect (EPR) (Maeda et al., 2009; Fang et al., 2011; Maeda et al., 2013).
Figure 1
PEG, which has been approved by the US Food and Drug Administration (FDA) for use in human, is the most commonly used hydrophilic component of polymeric micelles (Molineux, 2002; Duncan, 2014; Qu et al., 2018). It is biodegradable and biocompatible because it does not form toxic metabolites, and it is commercially available in molecular weights ranging from 500 to 20,000 Da. Surface modification of PEG-based nanocarriers can reduce interactions with plasma proteins and nonspecific uptake by the reticuloendothelial system, prolonging time in systemic circulation (Bae and Kataoka, 2009; Wang et al., 2018a). The multifunctionality of PEG allows multiple drug or targeting molecules to be conjugated to the same polymer chain. Currently, several PEG-derivatized polymeric micelles carrying anti-cancer drugs are under clinical evaluation, including NK012, NK105, SP1049C, NK911, and Genexol-PM (Cabral and Kataoka, 2014; Mohamed et al., 2014; Deshmukh et al., 2017). In fact, regulatory authorities in South Korea have approved Genexol-PM for use against breast cancer.
In the “hydrophilic shell-hydrophobic core” architecture of polymeric micelles, the hydrophobic core provides a loading space for poorly water-soluble drugs (Zhang et al., 2014d). The polymers most commonly used to build the hydrophobic core are polyesters and polyamides, such as polycaprolactone, poly(lactic acid), poly(glycolic acid), and poly(l-histidine) (Zhang and Zhuo, 2005; Zhang et al., 2014a; Zhang et al., 2014c). Most of these hydrophobic components are inert carrier materials without therapeutic activity. In other words, they add to the cost and toxicity risk of the drug delivery system, without contributing to therapeutic efficacy (Qu et al., 2017b). This has led researchers to explore nanocarriers that themselves have therapeutic effects.
Since Ringsdorf proposed the concept of “polymeric prodrug” in 1975, the utility of polymer-drug conjugates in clinical therapy has been well demonstrated (Hoste et al., 2004; Ringsdorf, 2010). Interestingly, hydrophobic drugs conjugated to hydrophilic polymers can self-assemble into micelles, which can then be loaded with another therapeutic molecule (Ulbrich and Subr, 2004; Greco and Vicent, 2008). Numerous bioactive hydrophobic agents have been conjugated to PEG to form so-called “dual-functional” micellar carriers, which have intrinsic antitumor activity and that deliver anti-tumor drug cargo (Mi et al., 2011; Huang et al., 2012; Chung et al., 2014; Zhang et al., 2014e). PEG-derivatized dual-functional micelles are typically prepared with one of two types of hydrophobic material (Qu et al., 2017b): anti-cancer natural products not yet used clinically, such as vitamin E succinate, (−)-epigallocatechin-3-gallate, embelin, and S-trans,trans-farnesylthiosalicylic acid, or anti-cancer molecules already established in the clinic, such as camptothecin (CPT), doxorubicin (DOX), paclitaxel (PTX), and docetaxel (Figure 2).
Figure 2
In this review, we summarize recent progress in PEG-derivatized dual-functional micellar carriers and their application in cancer therapy. Strategies to improve carrier–drug interactions are discussed because two challenges in the development of polymeric micelles are their drug-loading capacity and stability. Recent developments in exploiting dual-functional carriers for therapies combining immuno- and chemotherapy are also surveyed.
PEG-Derivatized Dual-Functional Micelles With Intrinsic Anti-Cancer Activity
PEG-Derivatized Vitamin E
Vitamin E succinate (D-α-tocopherol, α-TOS) is a derivative of vitamin E that shows activity against various types of cancers, including breast, lung, and prostate (Malafa and Neitzel, 2000; Malafa et al., 2002; Kline et al., 2004). α-TOS can selectively kill tumor cells without affecting normal cells by inhibiting angiogenesis, suppressing activation of NF-κB, and generating reactive oxygen species (Dong et al., 2007; Jin et al., 2014). It can also enhance the cytotoxicity of PTX and DOX (Kanai et al., 2010), and it can inhibit P-glycoprotein (P-gp) to overcome multidrug resistance (MDR) (Constantinides et al., 2006).
The poor water solubility of α-TOS has limited its use in vivo, leading researchers to explore possibilities with D-α-tocopheryl PEG succinate (vitamin E TPGS, or simply TPGS), which is a water-soluble derivative of α-TOS generated by esterification with PEG (Youk et al., 2005). TPGS acts as a nonionic surfactant: it exhibits amphipathic properties and can form micelles in aqueous media at a critical micelle concentration (CMC) of 0.2 mg/ml. It has been investigated as an absorption enhancer, emulsifier, solubilizer, additive and permeation enhancer, and stabilizer (Zhang et al., 2012; Guo et al., 2013). TPGS also inhibits P-gp-mediated drug efflux by inhibiting the ATPase of P-gp and mitochondrial respiratory complex II (Dong et al., 2008; Collnot et al., 2010). The relatively high CMC of TPGS and its relatively short PEG chains mean that TPGS-based micelles usually leave the circulation quickly and accumulate in the liver and spleen (Tan et al., 2017; Yang et al., 2018a). Therefore, TPGS is usually mixed with other lipids or copolymers to form micelles.
Research groups have taken different approaches to improving the properties of TPGS as a micelle carrier (Figure 3). Conjugating tocopheryl succinate to PEG 2000 leads to TPGS2K, which has a much lower CMC than TPGS, allowing formation of stable drug-loaded micelles without addition of other lipids or polymers. For example, one group developed TPGS2K polymer-based micelles with a CMC of only 0.0219 mg/ml (Mi et al., 2011). Docetaxel was successfully loaded in TPGS2K micelles to form a uniform sphere with an average diameter of 15 nm. In vitro antitumor results showed that docetaxel-loaded TPGS2K micelles dramatically decreased the IC50 values of MCF-7 cells (0.526 g/ml) compared with that of the free docetaxel (103.4 g/ml), indicating a synergistic therapeutic effect between TPGS2K and docetaxel. Another group conjugated PEG to two vitamin E molecules to form star-shaped copolymer PLV2K micelles with a CMC of only 1.14 μg/ml (Wang et al., 2012). DOX was encapsulated into the hydrophobic core of PLV2K with encapsulation efficiency as high as 94.5%, and the drug-loaded micelles inhibited growth of 4T1 breast cancer tumors in mice more effectively than free DOX or DOX-loaded in TPGS.
Figure 3
Screening two PEG lengths (PEG2K or PEG5K) and two molar ratios of PEG to vitamin E (1:1 or 1:2) identified PEG5K-VE2 micelles comprising one PEG5K and two vitamin E molecules as having the lowest CMC and most efficient PTX loading (Lu et al., 2013a; Lu et al., 2014c). Loading PTX into PEG5K-VE2 inhibited tumor growth in mice significantly better than loading it into PEG2K-VE or PEG5K-VE2, or than using Taxol. Our group has analyzed how the molar ratio of PEG to vitamin E affects the stability, drug loading capacity, and tumor targeting efficiency of TPGS-based micelles in vitro and in vivo (Li et al., 2016a; Li et al., 2016b). PAMV6, which is formulated with a 1:6 molar ratio of PEG to vitamin E and shows a wheat-like structure, showed the lowest CMC, greatest stability in serum, and highest tumor distribution and retention. Moreover, PAMV6 inhibits P-gp efflux activity, not by affecting P-gp expression, but by decreasing mitochondrial membrane potential and intracellular levels of ATP (Li et al., 2016a). As a result, pirarubicin-loaded PAMV6 micelles inhibited the growth of MCF-7/ADR xenograft tumors in mice significantly better than free pirarubicin, with significantly less systemic and organ-specific toxicity.
PEG-Derivatized EGCG
The most abundant catechin in green tea, (−)-epigallocatechin-3-gallate (EGCG), shows activity against cancer, diabetes, neurodegenerative disease, stroke, obesity, and other disorders (Chakrawarti et al., 2016; Song et al., 2017). EGCG can inhibit tumor growth and metastasis by interrupting key signaling and metabolic pathways that support cancer cell survival without damaging normal cells (Shankar et al., 2007; Wang et al., 2018b). For example, EGCG can down-regulate PEA15 expression and enhance TRAIL-mediated apoptosis in tumor cells (Siegelin et al., 2008; Le et al., 2018). EGCG interacts with the estrogen receptor to inhibit estrogen-induced proliferation of breast cancer cells and sensitize hormone-responsive tumors to drugs such as tamoxifen that target steroid receptors (Farabegoli et al., 2007; Tu et al., 2011).
Despite its clear therapeutic effects, EGCG remains far from clinical use, in large part because of its low stability and bioavailability. The several hydroxyl groups in EGCG make it highly hydrophilic, which resulted in short circulation half-time. One group developed a micellar nanocomplex (MNC) comprising two EGCG derivatives that bind to proteins in a spatially ordered structure (Chung et al., 2014). MNCs self-assemble in two steps: first, oligomerized EGCG (OEGCG) complexes with the humanized monoclonal therapeutic antibody Herceptin (trastuzumab) to form a core; second, PEG-EGCG assembles as a shell around this core. The resulting MNC is monodisperse and spherical, with a mean diameter of about 90 nm and good stability in serum at 37°C for 15 days. Both in vitro and in vivo therapeutic studies showed that Herceptin-MNC had superior anti-tumor effects to free Herceptin. While Herceptin on its own shows anti-tumor activity, it synergizes with the EGCG within MNC to cause even greater inhibition, with a combination index of 0.93. Similarly, replacing Herceptin with interferon α-2a generates an MNC that inhibits the growth of HAK-1B human liver cancer cells more than free interferon α-2a, with a combination index of 0.46.
EGCG inhibits P-gp (Jodoin et al., 2002) and can sensitize drug-resistant tumor cells to DOX and increase DOX accumulation in MDR cells (Liang et al., 2010; Song et al., 2017). Thus, combination therapy with EGCG and DOX may simultaneously overcome DOX-induced cardiotoxicity and MDR. Special methods are needed to co-load DOX and EGCG into micelles, since DOX is hydrophobic while EGCG is hydrophilic and unstable. To achieve such co-loading, a novel green tea catechin-based polyion complex was developed in which DOX and EGCG were co-loaded via electrostatic interactions as well as interactions between EGCG and poly(ethylene glycol)-block-poly(lysine-co-lysine-phenylboronic acid) (Cheng et al., 2016). This allowed DOX to be loaded into the micelles with a drug loading capacity of 12.4% and drug loading efficiency of 55%. The ability of EGCG to scavenge oxygen free radicals and inhibit P-gp means that these vesicles may simultaneously overcome DOX-induced cardiotoxicity and MDR (Mei et al., 2004; Yao et al., 2017).
PEG-Derivatized Embelin
Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone), a major active constituent of the Embelia ribes Burn plant, possesses analgesic, anti-diabetic, anti-inflammatory, and hepatoprotective activities (Chitra et al., 1994; Naik et al., 2013; Peng et al., 2014). It also inhibits growth of breast, colon, prostate, and pancreatic tumors via several different mechanisms. In most cases, the compound induces intrinsic or extrinsic apoptotic cell death and modulates signaling pathways involving NF-κB, p53, PI3K/AKT, and STAT3 (Heo et al., 2011; Kim et al., 2013; Ko et al., 2018). Interestingly, in silico screening predicts that embelin inhibits the X-linked inhibitor of apoptosis protein (XIAP), which is over-expressed in a variety of cancers, especially drug-resistant ones (Nikolovska-Coleska et al., 2004; Hussain et al., 2017). Several synthetic peptide inhibitors of XIAP have been reported, and some are in clinical trials, but embelin would be the only naturally occurring non-peptide XIAP inhibitor reported so far.
Embelin is poorly water-soluble and has limited oral bioavailability. Modifying it with PEG can significantly increase its water solubility, and the resulting PEG-embelin conjugates can self-assemble to form micelles and efficiently encapsulate hydrophobic drugs such as PTX and DOX (Huang et al., 2012). Screening two PEG lengths (PEG3.5K or PEG5K) and two molar ratios of PEG to EB (1:1 or 1:2) showed that PEG5K-EB2, in which two embelin molecules were linked via aspartic acid to one PEG5K, showed the lowest CMC and highest PTX loading efficiency (Lu et al., 2013b). When these micelles were loaded with PTX, the embelin and PTX synergized to inhibit cancer cell growth in vitro even when PTX were present at nanomolar concentrations. The same micelles also inhibited growth of 4T1 breast cancer tumors and PC-3 prostate cancer tumors in mice better than Taxol, with minimal toxicity.
To improve the targeting ability of PEG5K-EB2 micelles, folic acid (FA) was coupled to the surface and the resulting FA-PEG5K-EB2 were able to readily self-assemble to form nanomicelles with a particle diameter around 20 nm (Lu et al., 2014b). FA-PEG5K-EB2 significantly facilitated the intracellular uptake of DOX over free DOX and Doxil in breast cancer cells 4T1.2, and drug-resistant cells NCI/ADR-RES. Consistent with better tumor targeting, the FA-decorated micelles inhibited the growth of 4T1.2 metastatic breast cancer tumors in mice significantly more than free DOX, Doxil or the micelles without FA, and with lower toxicity.
PEG-embelin micelles, in addition to enhancing the anti-tumor efficacy of PTX or DOX, can also inhibit P-gp ATPase activity analogously to TPGS and thereby can sensitize drug-resistant NCI/ADR-RES cells to DOX (Lu et al., 2013b; Lu et al., 2014b). Further studies should clarify whether PEG-embelin micelles act as a non-competitive or competitive inhibitor of the P-gp ATPase.
PEG-Derivatized Farnesylthiosalicylic Acid
S-trans,trans-farnesylthiosalicylic acid (FTS) is a synthetic farnesylcysteine mimetic with strong potential to be an effective cancer drug (Kloog and Cox, 2000; Erlich et al., 2006). As a first-in-class Ras inhibitor, it is in phase II clinical trials to treat pancreatic cancer and lung adenocarcinoma (Riely et al., 2011; Laheru et al., 2012). FTS may also be effective against other cancers in which mutated Ras proteins are constitutively active (Simanshu et al., 2017), and it so far has shown minimal side effects (Gana-Weisz et al., 2002). FTS can also suppress cancer cell growth and proliferation by inhibiting mTOR, especially in endocrine-resistant breast cancer (Mcmahon et al., 2005).
Its long hydrophobic chains make FTS poorly water-soluble, so it is usually PEGylated when forming micelles (Figure 4). For example, conjugation two FTS to PEG via a labile ester linkage readily forms PEG5K-FTS2(L) micelles in aqueous solution, which inhibit tumor growth in mice to a similar extent as free FTS (Zhang et al., 2013). Loading these micelles with PTX or curcumin led to synergy between these compounds and the FTS, such that micelle cytotoxicity was higher than with PTX or curcumin on their own (Zhang et al., 2013; Chen et al., 2014). Breaking of the linkage between PEG and FTS appears to be critical for its anti-tumor activity: replacing the ester linkage with a more stable amide linkage resulted in significantly lower cytotoxicity (Zhang et al., 2013). It is likely that FTS is much more readily released from PEG5K-FTS2(L) than PEG5K-FTS2(S) with a stable amide linkage. In vitro, PEG5K-FTS2(L) alone was much more active than PEG5K-FTS2(S) in antitumor activity in both 4T1.2 and HCT-116 cell lines. In vivo, PTX formulated in PEG5K-FTS2(L) showed antitumor activity that is more potent than that of Taxol or PTX/PEG5K-FTS2(S). Glutathione is present in tumors at much higher concentrations than in extracellular fluids (Saito et al., 2003; Zhang et al., 2018b), so coupling the FTS to PEG via a disulfide linkage can lead to greater release of FTS inside tumor cells and therefore to greater cytotoxicity than either Taxol or PTX (Zhang et al., 2014g).
Figure 4
Screening of two weights of PEG (PEG2Kvs. PEG5K) and two molar ratios PEG: FTS (1:2 or 1:4) identified PEG5K-FTS4 as the stablest and most cytotoxic micelles against 4T1.2 breast cancer tumors in mice (Zhang et al., 2014e). Adding the 9-fluorenylmethoxycarbony (Fmoc) moiety to these micelles significantly improved the loading capacity of PTX and DOX as well as efficacy against breast and prostate cancer tumors in mice (Zhang et al., 2014f). Incorporating a disulfide linkage into Fmoc-modified PEG5K-FTS2 micelles reduced the CMC to 0.02 μM, which was 10-fold lower than the CMC of micelles without either the Fmoc moiety or disulfide linkage (Xu et al., 2017). It also increased accumulation inside prostate cancer tumors in mice by two- to three-fold. The disulfide linkage also increased the cytotoxicity in vitro and in vivo when Fmoc-modified micelles were loaded with PTX. These studies indicate that PEG-FTS is an effective dual-functional carrier that can synergize with co-delivered anti-cancer agents.
PEG-Derivatized Anticancer Drugs
Most small-molecule anti-cancer drugs are hydrophobic. Their water solubility and circulation time can be improved by creating PEGylated prodrug copolymers that self-assemble into micelles. These PEG-drug conjugates can also be used to carry additional chemotherapeutic agents (Table 1). Below, we discuss only PEGylated prodrug complexes to which additional drugs are added. PEGylated drug complexes without further drug addiction have been reviewed elsewhere.
Table 1
| Self-assembled prodrugs | Hydrophobic drug | Co-loaded drug | In vitro/in vivo experimental model | References |
|---|---|---|---|---|
| CPT-SS-PEG-SS-CPT | Camptothecin | Camptothecin | HepG2 human hepatoma cell model | (Li et al., 2011) |
| CPT-PEG-CPT | Camptothecin | Doxorubicin | Human cervical cancer Hela cells | (Dong et al., 2012) |
| mPEG-BC-PGluCPT | Camptothecin | Doxorubicin | HepG2 and HL-7702 cells | (Gao et al., 2018) |
| P(CPTMA-coPEMA) | Camptothecin | Glucose oxidase | A549 tumors | (Li et al., 2017) |
| PEG-bPTCPT | Camptothecin | β-lapachone | Mouse breast cancer 4T1 cell line and 4T1 tumor-bearing mice | (Yin et al., 2019) |
| PEG-PTX | Paclitaxel | Paclitaxel | MCF-7 cells and mouse xenograft tumor model bearing MCF-7 cells | (Lu et al., 2014a) |
| PEG-acetal-PTX | Paclitaxel | Paclitaxel | HeLa and MDA-MB-231 cells | (Huang et al., 2018) |
| mPEG-b-DOX | Doxorubicin | Verapamil | MCF-7/ADR cell line | (Zhao et al., 2015) |
| PEG-CH = N-DOX | Doxorubicin | 7-ethyl-10-hydroxyl-camptothecin | MCF-7 cells and mouse xenograft tumor model bearing MCF-7 cells | (Sun et al., 2018b) |
| PEG–DTX | Docetaxel | Docetaxel | H460 human non-small cell lung, SKOV-3 human ovarian and MCF-7 human breast cancer cells | (Liu et al., 2008) |
| PEG-CCM@APTES-COF-1 | Curcumin | Doxorubicin | HeLa cells and HeLa cell xenograft tumor mice model | (Zhang et al., 2018a) |
| PEG-Fmoc-GA | Glycyrrhizic acid | Doxorubicin | HepG2 cells human liver cancer xenograft model | (Yang et al., 2018b) |
Polyethylene glycol (PEG)-derivatized anticancer drug as dual-functional micellar carrier.
The natural cytotoxic quinolone alkaloid CPT inhibits DNA topoisomerase I, making it effective against a wide spectrum of cancers (Gromova et al., 1990; Pizzolato and Saltz, 2003; Zunino and Pratesi, 2004). However, the clinical use of CPT is limited by its extremely hydrophobicity and low stability in vivo (Koo et al., 2005; Botella and Rivero-Buceta, 2017). A CPT-PEG-CPT prodrug has been prepared by conjugating two molecules of CPT to the ends of PEG via degradable ester linkage (Dong et al., 2012). This complex, which can accommodate CPT up to 41%, self-assembled into micelles with a diameter of 50 nm. DOX was loaded into the micelles with high capacity, and the complex showed greater cytotoxicity than free DOX. The increased cytotoxicity might be induced by the combined effect of both DOX and CPT. Further, they introduced redox-responsive disulfide linkers and prepared a micellar system (CPT-SS-PEG-CPT) to achieve an aim of rapidly releasing the native CPT in tumor-relevant reductive conditions (Li et al., 2011). An amphiphilic prodrug of CPT has been prepared by polymerizing γ-CPT glutamate N-carboxyanhydride with mPEG via pH-sensitive boronate ester bonds (Gao et al., 2018). The resulting prodrug self-assembled into micelles, simultaneously encapsulating DOX. These micelles showed sustained drug release during 48 h, which increased when pH was reduced from 7.4 to 6.0. This approach may promote uptake of the micelles and drug release specifically in the acidic tumor microenvironment.
PTX, isolated from Taxus brevifolia, is one of the most effective chemotherapeutic drugs against ovarian, lung, breast, and other cancers (Wani et al., 1971; Blair and Deeks, 2015; Bourgeois-Daigneault et al., 2016). Its aqueous solubility is only about 0.3 mg/ml, so it is solubilized with polyoxyethylenated castor oil (Cremophor EL) in the commercial formulation of PTX, called Taxol. Cremophor EL can cause serious hypersensitivity, neurotoxicity, and nephrotoxicity, which severely limit the success of PTX chemotherapy (Singla et al., 2002; Nehate et al., 2014). To avoid these problems, mPEG5000 and PTX have been conjugated via succinic anhydride as linker, giving a water-soluble PTX prodrug (Greenwald et al., 1996). Although this prodrug appears to have negligible anti-tumor activity because PTX release is too low (Liang et al., 2012), the prodrug can complex with free PTX to form spherical particles of 100–200 nm (Lu et al., 2014a). These particles inhibited the growth of MCF-7 tumors in mice significantly better than Taxol, and with less toxicity. To allow breakage of the PEG-PTX bond under certain conditions, PEG and PTX have been conjugated using an acetal linker that cleaves preferentially when exposed to endosomal pH (Huang et al., 2018). This prodrug self-assembles into micelles and can encapsulate free PTX into the hydrophobic core, such that the total PTX concentration in the micelles reaches a capacity of 60.3%. These PTX-loaded micelles inhibited HeLa and MDA-MB-231 cells more than free PTX.
PEG-Derivatized Dual-Functional Micelles for Immunochemo-Therapy
Accumulation evidence suggests that chemotherapy-induced immune responses contribute to the overall anti-tumor effects of chemotherapy (Vanneman and Dranoff, 2012; Bracci et al., 2014; Kumar et al., 2017). However, cancer treatment also up-regulates various negative feedback mechanisms that limit the effectiveness of chemotherapy-elicited immune responses as well as other immunotherapies (Curran et al., 2010; Jiang et al., 2019). For example, indoleamine 2,3-dioxygenase (IDO) is a negative feedback protein that helps tumors evade the immune system, grow, and metastasize (Soliman et al., 2010; Ricciuti et al., 2019; Zhu et al., 2019); IDO causes immunosuppressive effects by inhibiting T cell differentiation and proliferation (Uyttenhove et al., 2003; Zamanakou et al., 2007). Reversing these negative feedback mechanisms may have anti-tumor effects. NLG919, a highly selective IDO inhibitor with a median effect concentration of 75 nM, promotes growth of T and natural killer cells, increases interferon production, and reduces conversion to a regulatory T cell phenotype (Mautino et al., 2013; Li et al., 2014; Meng et al., 2017). NLG919 is poorly water soluble, and it cannot be simply co-delivered as a mixture with drugs because of differences in physico-chemical and pharmacokinetic profiles (Liu et al., 2010).
NLG919 has been conjugated with PEG in a dual-functional, immunostimulatory micelle in which the Fmoc group was introduced to improve drug loading capacity and formulation stability (Chen et al., 2016). The resulted PEG2K-Fmoc-NLG micelles self-assembled in aqueous solutions to form particles of about 90 nm with a CMC of 0.737 mM. It’s found that PEG2K-Fmoc-NLG with a relatively labile ester linkage well retained the pharmacological activity of NLG919 and significantly enhanced T-cell immune responses. The micelles could also be loaded with several common drugs: PTX, docetaxel, DOX, gefitinib, imatinib, and curcumin. PTX-loaded PEG2K-Fmoc-NLG micelles were delivered intravenously into mice bearing breast cancer tumors or melanomas, and they showed significantly greater anti-tumor response than free PTX or the empty micelles without PTX.
These PTX-loaded micelles also enhanced anti-tumor immune responses, yet they triggered the counter-productive accumulation of myeloid-derived suppressor cells (MDSCs), which maintain a highly immunosuppressive tumor microenvironment (Pastaki Khoshbin et al., 2019; Safari et al., 2019; Groth et al., 2019). MDSCs can induce immunosuppression by up-regulating inducible nitric oxide synthase and arginase I, thereby inhibiting T-cell function (Meirow et al., 2015). MDSCs can enhance tumor cell proliferation, facilitate tumor metastasis and angiogenesis, and promote drug resistance (Draghiciu et al., 2015; Gabrilovich, 2017). Increased numbers of tumor-infiltrating MDSCs often correlate with high tumor burden and metastasis, contributing to poor prognosis (Nagaraj and Gabrilovich, 2008; Malek et al., 2016). To avoid stimulating MDSCs, a dual-functional carrier of PEG linked to NLG919 via an Fmoc moiety was loaded with both PTX and sunitinib (Chen et al., 2018), an FDA-approved tyrosine kinase inhibitor for the treatment of various cancers. Sunitinib reduces the level and activity of MDSCs and Treg cells systemically and in the tumor microenviroment (van Hooren et al., 2016; Motzer et al., 2017). These micelles then deliver three anti-tumor components to the cancer: PTX and sunitinib lead to synergistic killing of tumor cells as well as the induction of anti-tumor immune responses following the release and presentation of tumor antigens, sunitinib inhibits cytokines needed to recruit MDSCs, and NLG919 is released quite slowly to inhibit IDO and thereby sustain an immune-active tumor microenvironment.
In other studies, the dual-functional carrier of PEG-linked to NLG919 via an Fmoc moiety was loaded with DOX for immunochemotherapy against lymphoma (Zhai et al., 2017). The DOX-loaded micelles were small (<120 nm), showed sustained drug release, and triggered significantly large numbers of total CD4+/CD8+ T cells and functional CD4+/CD8+ T cells in mice with lymphoma than the same micelles without DOX. These micelles, whether loaded with DOX or not, reduced the recruitment of granulocytic MDSC and monocytic MDSCs to tumor tissues. This contrasts with the observation that the same micelles, when loaded with PTX, triggered the counter-productive accumulation of MDSCs (Chen et al., 2018). These differences may reflect the different abilities of DOX and PTX to modulate the immune system. More studies are needed to better understand the impact of different immunochemotherapies on the tumor microenvironment and overall anti-tumor effects.
PEG-Derivatized Dual-Functional Micelles With Improved Drug Loading Capacity
Dual-functional micelles not only exert intrinsic therapeutic effects, but also deliver other drugs to tumor sites. Most of these micelles load drugs via hydrophobic interaction, hydrogen bonding, and π-π stacking between the encapsulated drug and the hydrophobic components of the micelle (Lu et al., 2013a; Mohamed et al., 2014). This means that one way to improve drug loading capacity is to increase the density of the hydrophobic component. Conjugating PEG to multiple vitamin E molecules rather than one molecule improved drug loading capacity (Wang et al., 2012), and increasing the number of vitamin E, embelin, or FTS molecules conjugated to one PEG molecule increased drug loading capacity (Lu et al., 2013b; Lu et al., 2014c; Zhang et al., 2014e). We found that conjugating PEG to six vitamin E molecules (PAMV6) gave the highest drug loading capacity (Li et al., 2016b). The wheat-like structure of the hydrophobic chains of PAMV6 likely creates a binding pocket that enhances the interaction between carrier and loaded drug. However, increasing the number of conjugated vitamin E molecules to 10 (PAMV10) gave heterogeneous micelles, presumably because the balance between hydrophilic and hydrophobic chains was destroyed. These results suggest that increasing the density of the hydrophobic component can increase drug loading capacity only to a certain extent.
While the dual-functional micelles discussed so far in this review are effective in formulating drugs that are strongly hydrophobic, they are less effective at formulating moderately hydrophobic drugs. This can be improved by introducing hydrotropic motifs into the hydrohobic domain of polymeric micelles, which improves drug loading capacity and micelle stability (Cho et al., 2004; Huh et al., 2005). In fact, covalent coupling of the moderately hydrophobic DOX into the hydrophobic domain of polymeric micelles improves the loading capacity of free DOX (Yoo and Park, 2004b; Yoo and Park, 2004a).
Another way to improve drug-loading capacity and formulation stability is to incorporate a surfactant at the interface between carrier and drug (Gao et al., 2013). The Fmoc moiety, a functional group routinely used to protect amino acids, is one of the most potent drug-interacting motifs (Table 2). Fmoc-based micelles can effectively encapsulate six drugs with diverse structures: probucol, niclosamide, progesterone, cyclosporin A, nifedipine, and griseofulvin (Gao et al., 2013; Zhang et al., 2014b). Hydrophobic interactions and π-π stacking may contribute to drug-Fmoc interactions. Consistent with this idea, introduction of the Fmoc domain into PEG-derivatized vitamin E (Zhang et al., 2014f; Xu et al., 2017) and FTS carriers (Zhang et al., 2014i; Lu et al., 2015) improves their drug-loading capacity, probably because the Fmoc can engage in stacking interactions with the interfacial aromatic ring of vitamin E and FTS. A PEG-derivatized ibuprofen conjugate (PEG2K-FIbu) consisting of a hydrophilic PEG segment, Fmoc motif, and hydrophobic ibuprofen domain readily formed stable micelles with PTX in the nanosize range (∼100 nm) to a relatively high loading capacity of 67% (Zhao et al., 2016). In vitro cytotoxicity showed that PTX formulated in PEG2K-FIbu micelles was comparable to Taxol in inhibiting the proliferation of tumor cells. The lack of synergy between the ibuprofen-based carrier and PTX is likely due to the very low concentrations of carriers used in the cytotoxicity study. In vivo, PTX-loaded PEG2K-FIbu micelles showed a much more pronounced therapeutic efficacy compared with Taxol formulation. The improved antitumor activity of PTX-loaded PEG2K-FIbu micelles is likely attributed to the enhanced delivery of PTX to the tumors and the potential synergy between the micellar carrier and PTX.
Table 2
| PEG-derivatized micellar carriers | Hydrophobic segment | Co-loaded drug | Drug loading capacity | Drug loading efficiency | References |
|---|---|---|---|---|---|
| PEG5K-Fmoc-VE2 | Vitamin E | Doxorubicin | 39.9% | 79.5% | (Lu et al., 2014c) |
| PEG5K-(Fmoc-VE)2 | Vitamin E | Paclitaxel | 20.8% | 80.7% | (Zhang et al., 2014i) |
| PEG5K-Fmoc-VE2 | Vitamin E | Camptothecin | 9.2% | 70.5% | (Lu et al., 2015) |
| PEG5K-Fmoc-FTS2 | S-trans,transfarnesylthiosalicylic acid | Paclitaxel Doxorubicin | 12.1% 32.8% | 55.4% 69.7% | (Zhang et al., 2014f) |
| PEG5K-Fmoc-S-S-FTS2 | S-trans,transfarnesylthiosalicylic acid | Paclitaxel | 34.0% | 53.5% | (Xu et al., 2017) |
| PEG-Fmoc-GA | Glycyrrhizic acid | Doxorubicin | 7.3% | 93.2% | (Yang et al., 2018b) |
| PEG2K-Fmoc-NLG | NLG919 | Paclitaxel | 24.7% | – | (Chen et al., 2016) |
| PEG2K-Fmoc-NLG | NLG919 | Paclitaxel | 5.6% | 98.3% | |
| Sunitinib | 8.0% | 96.4% | (Chen et al., 2018) | ||
| PEG2K-Fmoc-NLG | NLG919 | Doxorubicin | 15.6% | 93.6% | (Zhai et al., 2017) |
| PEG2K-Fmoc-Ibu | Ibuprofen | Paclitaxel | 67.3% | 88.4% | (Zhao et al., 2016) |
Fmoc-based PEG-derivatized dual-functional micellar systems.
Challenges and Future Considerations of Dual-Functional Micellar Carrier
A large number of preclinical studies on dual-functional micelles have been published, which showed great promise to be an effective nanomedicine platform for drug delivery and cancer therapy. However, the clinical translation and desired therapeutic effects of dual-functional micelles are still far from satisfactory (Cabral and Kataoka, 2014). Micellar system share the limitations inherent to other nanodelivery system which mainly rely on the passive targeting of tumors based on the EPR effect (Fang et al., 2011). Poor tumor penetration due to high interstitial pressure and inefficient tumor cell uptake as well as off target liver and spleen accumulations have been repeatedly reported with the use of micelles (Taurin et al., 2012). The targeting effect in human sometimes is not as pronounced as that obtained in the simple cell or animal models due to the complexity of the human body. To this end, ligand-installed polymeric micelles have the potential for overcoming such biological barriers by taking advantage of receptor-mediated active target mechanisms (Deshayes et al., 2013). The end-group of the PEG segment can be readily modified with ligands capable of recognition of cell-specific surface receptors, providing cellular selectivity and superior intracellular delivery to dual-functional polymeric micelles. The effect of various ligands, including peptides, antibody fragments, and small molecules, installed on nanocarriers, has been confirmed to improve their targeting efficiency (Allen, 2002; Bae et al., 2005). For example, cyclic-RGD (cRGD) peptides have been recognized as specific ligands for integrin αvβ3 which is overexpressed in neovasculature and tumor cells (Kulhari et al., 2015; Li et al., 2019). cRGD-modified polymeric micelles loaded with DACHPt not only enhanced the cellular uptake of micelles by cancer cells, but also achieved efficient drug delivery in a mouse model of glioblastoma (Miura et al., 2013). Even though glioblastoma is notorious for its poor permeability due to the presence of the blood–brain tumor barrier, these cRGD-installed micelles rapidly penetrated and accumulated within tumor tissues.
Besides, the premature drug release in the bloodstream and inadequate drug release in the tumor may also account for the inferior therapeutic effects in human patients. Most of toxicities reported in clinical trials resulted from the micelle releasing the drug in the blood, causing toxic side effects similar to the free drug and thereby deviate from tumor targeting (Miller et al., 2013). Ideally, the drug is retained in the polymeric micelles during circulation but is released after accumulation in the tumor interstitium. The design of stimuli-responsive nanomicellar carriers is a very effective way to achieve tumor-targeted drug delivery and adequate release (Zhou et al., 2018a). Numerous stimuli-responsive dual-functional nanomicelles have been developed to deliver anticancer drug in response to a variety of extra/intracellular stimuli or external triggers, including pH, redox potential, enzymes, temperature, light, ultrasound, and magnetic field (Kalhapure and Renukuntla, 2018). It is reported that the microenvironment of most solid tumors is intrinsically acidic (pH 6.5–7.2), while the pH value in the blood and normal tissue is about 7.4. An even lower acidic pH is found in endosomes and lysosomes (pH 4.5–6.5) (Qu et al., 2017a; Liang et al., 2019). Accordingly, the difference in pH has been widely exploited to achieve tumor site- or organelle-specific activation of pH-responsive nanomicelles. Yang et al. developed a novel multifunctional pH-sensitive nanomicelle based on luteinizing hormone-releasing hormone (LHRH)-PEG-PHis-DOX/DOX-trans-activating transcriptional activator (TAT) acid-sensitive micelle, which could dissociate and release DOX-TAT when responding to the tumor extracellular pH (Yang et al., 2015). Such systems could efficiently go across the cell membrane and reach the cytosol of the multidrug-resistant cancer cells, resulting in the remarkable antitumor efficacy and negligible systematic toxicity.
In addition, PEG is believed to provide a steric barrier around the nanocarriers, and thus prolonging their blood circulation time. However, there was an unexpected pharmacokinetic alteration brought about with a second dose of PEGylated nanoparticles, the so-called accelerated blood clearance (ABC) phenomenon (Ishida and Kiwada, 2008). With this phenomenon, a second dose of PEG-derivatized nanomicelles, PEGylated liposomes, or PEG-containing microemulsions is rapidly cleared from circulation when administered within a certain time interval from injection of the first dose due to an enhanced accumulation in the liver (Abu Lila et al., 2013). Many attempts have focused on the use of other polymers, such as chitosan and hyaluronic acid, to replace PEG modification and to avoid the occurrence of the ABC phenomenon (Dong et al., 2016). Moreover, polyetherimide-based dual-functional carrier is an alternative strategy for the delivery of charged macromolecules, such as antisense oligonucleotides, plasmid DNA, and siRNA/miRNA (Zhou et al., 2018b). David Oupicky’s group developed many polycationic CXCR4 antagonist based dual-functional nanomicellar carriers that can simultaneously deliver siRNA and inhibit CXCR4 to achieve combination anticancer therapy (Li et al., 2012; Zhou et al., 2018b). Such dual-function delivery vectors could enhance antimetastatic efficacy of a variety of cancer gene therapy methods (Li and Oupicky, 2014; Sun et al., 2018a).
Conclusions
Dual-functional nanomicelles have emerged as a versatile and powerful platform for cancer therapy. They can self-assemble and efficiently encapsulate chemotherapeutic agents such as PTX and DOX into their hydrophobic core. They exert anti-tumor effects by virtue of the encapsulated drug as well as the intrinsic anti-cancer activity of carrier materials in the micelles. As a result, these micelle systems can enhance the efficacy of anti-tumor drugs while reducing their systemic toxicity; in fact, the carrier materials and drug cargo can synergize to increase efficacy.
Most of these dual-functional micelles rely on passive targeting, so more effective strategies are needed to enhance their targeted delivery, deepen their penetration into the tumor, and enable drug release in response to specific stimuli. Much work remains to be done to translate these promising nanomaterials into the clinic, including scale-up for industrial production and validation studies in appropriate animal models.
Funding
This work was financially supported by the National Natural Science Foundation of China (81603035 and 81870599), China Postdoctoral Fellowship (2017M612981 and 2018T110986).
Statements
Author contributions
YL and JH wrote the manuscript and obtained funding, TZ and QL contributed to the discussion and review of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Abu LilaA. S.KiwadaH.IshidaT. (2013). The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release172, 38–47. doi: 10.1016/j.jconrel.2013.07.026
2
AllenT. M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer2, 750–763. doi: 10.1038/nrc903
3
BaeY.JangW. D.NishiyamaN.FukushimaS.KataokaK. (2005). Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst.1, 242–250. doi: 10.1039/b500266d
4
BaeY.KataokaK. (2009). Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliv. Rev.61, 768–784. doi: 10.1016/j.addr.2009.04.016
5
BiswasS.KumariP.LakhaniP. M.GhoshB. (2016). Recent advances in polymeric micelles for anti-cancer drug delivery. Eur. J. Pharm. Sci.83, 184–202. doi: 10.1016/j.ejps.2015.12.031
6
BlairH. A.DeeksE. D. (2015). Albumin-bound Paclitaxel: a review in non-small cell lung cancer. Drugs75, 2017–2024. doi: 10.1007/s40265-015-0484-9
7
BotellaP.Rivero-BucetaE. (2017). Safe approaches for camptothecin delivery: structural analogues and nanomedicines. J. Control. Release247, 28–54. doi: 10.1016/j.jconrel.2016.12.023
8
Bourgeois-DaigneaultM. C.St-GermainL. E.RoyD. G.PelinA.AitkenA. S.ArulanandamR.et al. (2016). Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Res18, 83. doi: 10.1186/s13058-016-0744-y
9
BracciL.SchiavoniG.SistiguA.BelardelliF. (2014). Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ.21, 15–25. doi: 10.1038/cdd.2013.67
10
CabralH.KataokaK. (2014). Progress of drug-loaded polymeric micelles into clinical studies. J. Control. Release190, 465–476. doi: 10.1016/j.jconrel.2014.06.042
11
CagelM.TesanF. C.BernabeuE.SalgueiroM. J.ZubillagaM. B.MorettonM. A.et al. (2017). Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur. J. Pharm. Biopharm.113, 211–228. doi: 10.1016/j.ejpb.2016.12.019
12
ChabnerB. A.RobertsT. G.Jr. (2005). Chemotherapy and the war on cancer. Nat. Rev. Cancer5, 65. doi: 10.1038/nrc1529
13
ChakrawartiL.AgrawalR.DangS.GuptaS.GabraniR. (2016). Therapeutic effects of EGCG: a patent review. Expert Opin. Ther. Pat.26, 907–916. doi: 10.1080/13543776.2016.1203419
14
ChengY.JiY. (2019). RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics. Eur. J. Pharm. Sci.128, 8–17. doi: 10.1016/j.ejps.2018.11.023
15
ChenY.SunJ.HuangY.LuB.LiS. (2018). Improved cancer immunochemotherapy via optimal co-delivery of chemotherapeutic and immunomodulatory agents. Mol. Pharm.15, 5162–5173. doi: 10.1021/acs.molpharmaceut.8b00717
16
ChenY.XiaR.HuangY.ZhaoW.LiJ.ZhangX.et al. (2016). An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat. Commun.7, 13443. doi: 10.1038/ncomms13443
17
ChenY.ZhangX.LuJ.HuangY.LiJ.LiS. (2014). Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system. AAPS J.16, 600–608. doi: 10.1208/s12248-014-9595-6
18
ChengT.LiuJ.RenJ.HuangF.OuH.DingY.et al. (2016). Green tea catechin-based complex micelles combined with doxorubicin to overcome cardiotoxicity and multidrug resistance. Theranostics6, 1277–1292. doi: 10.7150/thno.15133
19
ChitraM.SukumarE.SujaV.DeviC. S. (1994). Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy40, 109–113. doi: 10.1159/000239181
20
ChoY. W.LeeJ.LeeS. C.HuhK. M.ParkK. (2004). Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J. Control. Release97, 249–257. doi: 10.1016/j.jconrel.2004.03.013
21
ChungJ. E.TanS.GaoS. J.YongvongsoontornN.KimS. H.LeeJ. H.et al. (2014). Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy. Nat. Nanotechnol.9, 907–912. doi: 10.1038/nnano.2014.208
22
CollnotE. M.BaldesC.SchaeferU. F.EdgarK. J.WempeM. F.LehrC. M. (2010). Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol. Pharm.7, 642–651. doi: 10.1021/mp900191s
23
ConstantinidesP. P.HanJ.DavisS. S. (2006). Advances in the use of tocols as drug delivery vehicles. Pharm. Res.23, 243–255. doi: 10.1007/s11095-005-9262-9
24
CurranM. A.MontalvoW.YagitaH.AllisonJ. P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A.107, 4275–4280. doi: 10.1073/pnas.0915174107
25
DeshayesS.CabralH.IshiiT.MiuraY.KobayashiS.YamashitaT.et al. (2013). Phenylboronic acid-installed polymeric micelles for targeting sialylated epitopes in solid tumors. J. Am. Chem. Soc.135, 15501–15507. doi: 10.1021/ja406406h
26
DeshmukhA. S.ChauhanP. N.NoolviM. N.ChaturvediK.GangulyK.ShuklaS. S.et al. (2017). Polymeric micelles: basic research to clinical practice. Int. J. Pharm.532, 249–268. doi: 10.1016/j.ijpharm.2017.09.005
27
DongH.DongC.YueF.RenT.ZhangZ.LanL.et al. (2012). Engineering of peglayted camptothecin into core–shell nanomicelles for improving solubility, stability and combination delivery. MedChemComm3, 1555. doi: 10.1039/c2md20153d
28
DongL. F.LowP.DyasonJ. C.WangX. F.ProchazkaL.WittingP. K.et al. (2008). Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene27, 4324–4335. doi: 10.1038/onc.2008.69
29
DongL. F.SwettenhamE.EliassonJ.WangX. F.GoldM.MedunicY.et al. (2007). Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res.67, 11906–11913. doi: 10.1158/0008-5472.CAN-07-3034
30
DongR.ZhaoX.GuoB.MaP. X. (2016). Self-healing conductive injectable hydrogels with antibacterial activity as cell delivery carrier for cardiac cell therapy. ACS Appl. Mater. Interfaces8, 17138–17150. doi: 10.1021/acsami.6b04911
31
DraghiciuO.LubbersJ.NijmanH. W.DaemenT. (2015). Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology4, e954829. doi: 10.4161/21624011.2014.954829
32
DuncanR. (2014). Polymer therapeutics: top 10 selling pharmaceuticals - what next? J. Control. Release190, 371–380. doi: 10.1016/j.jconrel.2014.05.001
33
ErlichS.Tal-OrP.LieblingR.BlumR.KarunagaranD.KloogY.et al. (2006). Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem. Pharmacol.72, 427–436. doi: 10.1016/j.bcp.2006.05.007
34
FangJ.NakamuraH.MaedaH. (2011). The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev.63, 136–151. doi: 10.1016/j.addr.2010.04.009
35
FarabegoliF.BarbiC.LambertiniE.PivaR. (2007). (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect. Prev.31, 499–504. doi: 10.1016/j.cdp.2007.10.018
36
GabrilovichD. I. (2017). Myeloid-derived suppressor cells. Cancer Immunol. Res.5, 3–8. doi: 10.1158/2326-6066.CIR-16-0297
37
Gana-WeiszM.Halaschek-WienerJ.JansenB.EladG.HaklaiR.KloogY. (2002). The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin. Cancer Res.8, 555–565. doi: 10.1093/carcin/23.2.373-A
38
GaoX.HuangY.MakhovA. M.EpperlyM.LuJ.GrabS.et al. (2013). Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers. Mol. Pharm.10, 187–198. doi: 10.1021/mp300319m
39
GaoY.XiaoY.LiuS.YuJ. (2018). Camptothecin prodrug nanomicelle based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake. J. Biomater. Sci. Polym. Ed.29, 160–180. doi: 10.1080/09205063.2017.1406632
40
Geszke-MoritzM.MoritzM. (2016). Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater. Sci. Eng. C Mater. Biol. Appl.68, 982–994. doi: 10.1016/j.msec.2016.05.119
41
GongJ.ChenM.ZhengY.WangS.WangY. (2012). Polymeric micelles drug delivery system in oncology. J. Control. Release159, 312–323. doi: 10.1016/j.jconrel.2011.12.012
42
GothwalA.KhanI.GuptaU. (2016). Polymeric micelles: recent advancements in the delivery of anticancer drugs. Pharm. Res.33, 18–39. doi: 10.1007/s11095-015-1784-1
43
GrecoF.VicentM. J. (2008). Polymer-drug conjugates: current status and future trends. Front. Biosci.13, 2744–2756. doi: 10.2741/2882
44
GreenwaldR. B.GilbertC. W.PendriA.ConoverC. D.XiaJ.MartinezA. (1996). Drug delivery systems: water soluble taxol 2’-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem.39, 424–431. doi: 10.1021/jm950475e
45
GromovaIiBuchmanV. L.AbagyanR. A.UlyanovA. V.BronsteinI. B. (1990). Sequence dependent modulating effect of camptothecin on the DNA-cleaving activity of the calf thymus type I topoisomerase. Nucleic Acids Res.18, 637–645. doi: 10.1093/nar/18.3.637
46
GrothC.HuX.WeberR.FlemingV.AltevogtP.UtikalJ.et al. (2019). Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer120, 16–25. doi: 10.1038/s41416-018-0333-1
47
GuoY.LuoJ.TanS.OtienoB. O.ZhangZ. (2013). The applications of vitamin E TPGS in drug delivery. Eur. J. Pharm. Sci.49, 175–186. doi: 10.1016/j.ejps.2013.02.006
48
HeoJ. Y.KimH. J.KimS. M.ParkK. R.ParkS. Y.KimS. W.et al. (2011). Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Lett.308, 71–80. doi: 10.1016/j.canlet.2011.04.015
49
HosteK.De WinneK.SchachtE. (2004). Polymeric prodrugs. Int. J. Pharm.277, 119–131. doi: 10.1016/j.ijpharm.2003.07.016
50
HuangD.ZhuangY.ShenH.YangF.WangX.WuD. (2018). Acetal-linked PEGylated paclitaxel prodrugs forming free-paclitaxel-loaded pH-responsive micelles with high drug loading capacity and improved drug delivery. Mater. Sci. Eng. C Mater. Biol. Appl.82, 60–68. doi: 10.1016/j.msec.2017.08.063
51
HuangY.LuJ.GaoX.LiJ.ZhaoW.SunM.et al. (2012). PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug. Chem.23, 1443–1451. doi: 10.1021/bc3000468
52
HuhK. M.LeeS. C.ChoY. W.LeeJ.JeongJ. H.ParkK. (2005). Hydrotropic polymer micelle system for delivery of paclitaxel. J. Control. Release101, 59–68. doi: 10.1016/j.jconrel.2004.07.003
53
HussainA. R.SirajA. K.AhmedM.BuR.PratheeshkumarP.AlrashedA. M.et al. (2017). XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer17, 640. doi: 10.1186/s12885-017-3627-4
54
IshidaT.KiwadaH. (2008). Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm.354, 56–62. doi: 10.1016/j.ijpharm.2007.11.005
55
JiangX.WangJ.DengX.XiongF.GeJ.XiangB.et al. (2019). Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol. Cancer18, 10. doi: 10.1186/s12943-018-0928-4
56
JinX.SongL.LiuX.ChenM.LiZ.ChengL.et al. (2014). Protective efficacy of vitamins C and E on p,p’-DDT-induced cytotoxicity via the ROS-mediated mitochondrial pathway and NF-kappaB/FasL pathway. PLoS One9, e113257. doi: 10.1371/journal.pone.0113257
57
JodoinJ.DemeuleM.BeliveauR. (2002). Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta1542, 149–159. doi: 10.1016/S0167-4889(01)00175-6
58
KalhapureR. S.RenukuntlaJ. (2018). Thermo- and pH dual responsive polymeric micelles and nanoparticles. Chem. Biol. Interact.295, 20–37. doi: 10.1016/j.cbi.2018.07.016
59
KanaiK.KikuchiE.MikamiS.SuzukiE.UchidaY.KodairaK.et al. (2010). Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo. Cancer Sci.101, 216–223. doi: 10.1111/j.1349-7006.2009.01362.x
60
KedarU.PhutaneP.ShidhayeS.KadamV. (2010). Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine6, 714–729. doi: 10.1016/j.nano.2010.05.005
61
KimS. W.KimS. M.BaeH.NamD.LeeJ. H.LeeS. G.et al. (2013). Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades. Prostate73, 296–305. doi: 10.1002/pros.22574
62
KlineK.YuW.SandersB. G. (2004). Vitamin E and breast cancer. J. Nutr.134, 3458s–3462s. doi: 10.1093/jn/134.12.3458S
63
KloogY.CoxA. D. (2000). RAS inhibitors: potential for cancer therapeutics. Mol. Med. Today6, 398–402. doi: 10.1016/S1357-4310(00)01789-5
64
KoJ. H.LeeS. G.YangW. M.UmJ. Y.SethiG.MishraS.et al. (2018). The application of embelin for cancer prevention and therapy. Molecules23, E621. doi: 10.3390/molecules23030621
65
KooO. M.RubinsteinI.OnyukselH. (2005). Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine1, 77–84. doi: 10.1016/j.nano.2004.11.002
66
KulhariH.PoojaD.ShrivastavaS.TelukutalaS. R.BaruiA. K.PatraC. R.et al. (2015). Cyclic-RGDfK peptide conjugated succinoyl-TPGS nanomicelles for targeted delivery of docetaxel to integrin receptor over-expressing angiogenic tumours. Nanomedicine11, 1511–1520. doi: 10.1016/j.nano.2015.04.007
67
KumarA.SirohiV. K.AnumF.SinghP. K.GuptaK.GuptaD.et al. (2017). Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin loaded amphiphilic mixed micelles for subjugating endometrial cancer. Nanomedicine13, 1953–1963. doi: 10.1016/j.nano.2017.04.014
68
LaheruD.ShahP.RajeshkumarN. V.McallisterF.TaylorG.GoldsweigH.et al. (2012). Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest. New Drugs30, 2391–2399. doi: 10.1007/s10637-012-9818-6
69
LeC. T.LeendersW. P. J.MolenaarR. J.Van NoordenC. J. F. (2018). Effects of the green tea polyphenol epigallocatechin-3-gallate on glioma: a critical evaluation of the literature. Nutr. Cancer70, 317–333. doi: 10.1080/01635581.2018.1446090
70
LiJ.LiY.WangY.KeW.ChenW.WangW.et al. (2017). Polymer prodrug-based nanoreactors activated by tumor acidity for orchestrated oxidation/chemotherapy. Nano Lett.17, 6983–6990. doi: 10.1021/acs.nanolett.7b03531
71
LiJ.OupickyD. (2014). Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor. Biomaterials35, 5572–5579. doi: 10.1016/j.biomaterials.2014.03.047
72
LiJ.ZhuY.HazeldineS. T.LiC.OupickyD. (2012). Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. Angew. Chem. Int. Ed. Engl.51, 8740–8743. doi: 10.1002/anie.201203463
73
LiM.BolducA. R.HodaM. N.GambleD. N.DoliscaS. B.BolducA. K.et al. (2014). The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J. Immunother. Cancer2, 21. doi: 10.1186/2051-1426-2-21
74
LiX. Q.WenH. Y.DongH. Q.XueW. M.PaulettiG. M.CaiX. J.et al. (2011). Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism. Chem. Commun. (Camb.)47, 8647–8649. doi: 10.1039/c1cc12495a
75
LiY.LiR.LiuQ.LiW.ZhangT.ZouM.et al. (2016a). One-step self-assembling nanomicelles for pirarubicin delivery to overcome multidrug resistance in breast cancer. Mol. Pharm.13, 3934–3944. doi: 10.1021/acs.molpharmaceut.6b00712
76
LiY.LiuQ.LiW.ZhangT.LiH.LiR.et al. (2016b). Design and validation of PEG-derivatized vitamin E copolymer for drug delivery into breast cancer. Bioconjug. Chem.27, 1889–1899. doi: 10.1021/acs.bioconjchem.6b00292
77
LiY.PuS.LiuQ.LiR.ZhangJ.WuT.et al. (2019). An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J. Control. Release303, 77–90. doi: 10.1016/j.jconrel.2019.04.022
78
LiangG.TangA.LinX.LiL.ZhangS.HuangZ.et al. (2010). Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol.37, 111–123. doi: 10.3892/ijo_00000659
79
LiangL.LinS. W.DaiW.LuJ. K.YangT. Y.XiangY.et al. (2012). Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J. Control. Release160, 618–629. doi: 10.1016/j.jconrel.2012.02.020
80
LiangY.ZhaoX.MaP. X.GuoB.DuY.HanX. (2019). pH-responsive injectable hydrogels with mucosal adhesiveness based on chitosan-grafted-dihydrocaffeic acid and oxidized pullulan for localized drug delivery. J. Colloid Interface Sci.536, 224–234. doi: 10.1016/j.jcis.2018.10.056
81
LiuJ.ZahediP.ZengF.AllenC. (2008). Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J. Pharm. Sci.97, 3274–3290. doi: 10.1002/jps.21245
82
LiuX.ShinN.KoblishH. K.YangG.WangQ.WangK.et al. (2010). Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood115, 3520–3530. doi: 10.1182/blood-2009-09-246124
83
LuJ.ChuanX.ZhangH.DaiW.WangX.WangX.et al. (2014a). Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Int. J. Pharm.471, 525–535. doi: 10.1016/j.ijpharm.2014.05.032
84
LuJ.HuangY.ZhaoW.ChenY.LiJ.GaoX.et al. (2013a). Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol. Pharm.10, 2880–2890. doi: 10.1021/mp300729y
85
LuJ.HuangY.ZhaoW.MarquezR. T.MengX.LiJ.et al. (2013b). PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials34, 1591–1600. doi: 10.1016/j.biomaterials.2012.10.073
86
LuJ.LiuC.WangP.GhazwaniM.XuJ.HuangY.et al. (2015). The self-assembling camptothecin-tocopherol prodrug: an effective approach for formulating camptothecin. Biomaterials62, 176–187. doi: 10.1016/j.biomaterials.2015.05.046
87
LuJ.ZhaoW.HuangY.LiuH.MarquezR.GibbsR. B.et al. (2014b). Targeted delivery of doxorubicin by folic acid-decorated dual functional nanocarrier. Mol. Pharm.11, 4164–4178. doi: 10.1021/mp500389v
88
LuJ.ZhaoW.LiuH.MarquezR.HuangY.ZhangY.et al. (2014c). An improved D-alpha-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J. Control. Release196, 272–286. doi: 10.1016/j.jconrel.2014.10.016
89
MaedaH.BharateG. Y.DaruwallaJ. (2009). Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm.71, 409–419. doi: 10.1016/j.ejpb.2008.11.010
90
MaedaH.NakamuraH.FangJ. (2013). The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev.65, 71–79. doi: 10.1016/j.addr.2012.10.002
91
MalafaM. P.FokumF. D.MowlaviA.AbusiefM.KingM. (2002). Vitamin E inhibits melanoma growth in mice. Surgery131, 85–91. doi: 10.1067/msy.2002.119191
92
MalafaM. P.NeitzelL. T. (2000). Vitamin E succinate promotes breast cancer tumor dormancy. J. Surg. Res.93, 163–170. doi: 10.1006/jsre.2000.5948
93
MalekE.De LimaM.LetterioJ. J.KimB. G.FinkeJ. H.DriscollJ. J.et al. (2016). Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev.30, 341–348. doi: 10.1016/j.blre.2016.04.002
94
MautinoM. R.JaipuriF. A.WaldoJ.KumarS.LinkC. J. (2013). Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res.73, 491–491. doi: 10.1158/1538-7445.AM2013-491
95
McmahonL. P.YueW.SantenR. J.LawrenceJ. C.Jr. (2005). Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol. Endocrinol.19, 175–183. doi: 10.1210/me.2004-0305
96
MeiY.QianF.WeiD.LiuJ. (2004). Reversal of cancer multidrug resistance by green tea polyphenols. J. Pharm. Pharmacol.56, 1307–1314. doi: 10.1211/0022357044364
97
MeirowY.KantermanJ.BaniyashM. (2015). Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Front. Immunol.6, 523. doi: 10.3389/fimmu.2015.00523
98
MengX.DuG.YeL.SunS.LiuQ.WangH.et al. (2017). Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. Int. J. Immunopathol. Pharmacol.30, 215–226. doi: 10.1177/0394632017714696
99
MiY.LiuY.FengS. S. (2011). Formulation of docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials32, 4058–4066. doi: 10.1016/j.biomaterials.2011.02.022
100
MillerT.BreyerS.Van ColenG.MierW.HaberkornU.GeisslerS.et al. (2013). Premature drug release of polymeric micelles and its effects on tumor targeting. Int. J. Pharm.445, 117–124. doi: 10.1016/j.ijpharm.2013.01.059
101
MiuraY.TakenakaT.TohK.WuS.NishiharaH.KanoM. R.et al. (2013). Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano7, 8583–8592. doi: 10.1021/nn402662d
102
MohamedS.ParayathN. N.TaurinS.GreishK. (2014). Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Ther. Deliv.5, 1101–1121. doi: 10.4155/tde.14.69
103
MolineuxG. (2002). Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev.28Suppl A, 13–16. doi: 10.1016/S0305-7372(02)80004-4
104
MotzerR. J.EscudierB.GannonA.FiglinR. A. (2017). Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma. Oncologist22, 41–52. doi: 10.1634/theoncologist.2016-0197
105
NagarajS.GabrilovichD. I. (2008). Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res.68, 2561–2563. doi: 10.1158/0008-5472.CAN-07-6229
106
NaikS. R.NitureN. T.AnsariA. A.ShahP. D. (2013). Anti-diabetic activity of embelin: involvement of cellular inflammatory mediators, oxidative stress and other biomarkers. Phytomedicine20, 797–804. doi: 10.1016/j.phymed.2013.03.003
107
NehateC.JainS.SanejaA.KhareV.AlamN.DubeyR. D.et al. (2014). Paclitaxel formulations: challenges and novel delivery options. Curr. Drug Deliv.11, 666–686. doi: 10.2174/1567201811666140609154949
108
Nikolovska-ColeskaZ.XuL.HuZ.TomitaY.LiP.RollerP. P.et al. (2004). Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem.47, 2430–2440. doi: 10.1021/jm030420+
109
Pastaki KhoshbinA.EskianM.Keshavarz-FathiM.RezaeiN. (2019). Roles of myeloid-derived suppressor cells in cancer metastasis: immunosuppression and beyond. Arch. Immunol. Ther. Exp. (Warsz.)67, 89–102. doi: 10.1007/s00005-018-0531-9
110
PengM.HuangB.ZhangQ.FuS.WangD.ChengX.et al. (2014). Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. Cancer Lett.354, 407–416. doi: 10.1016/j.canlet.2014.08.011
111
PizzolatoJ. F.SaltzL. B. (2003). The camptothecins. Lancet361, 2235–2242. doi: 10.1016/S0140-6736(03)13780-4
112
QuJ.ZhaoX.LiangY.ZhangT.MaP. X.GuoB. (2018). Antibacterial adhesive injectable hydrogels with rapid self-healing, extensibility and compressibility as wound dressing for joints skin wound healing. Biomaterials183, 185–199. doi: 10.1016/j.biomaterials.2018.08.044
113
QuJ.ZhaoX.MaP. X.GuoB. (2017a). pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy. Acta Biomater.58, 168–180. doi: 10.1016/j.actbio.2017.06.001
114
QuY.ChuB.ShiK.PengJ.QianZ. (2017b). Recent progress in functional micellar carriers with intrinsic therapeutic activities for anticancer drug delivery. J. Biomed. Nanotechnol.13, 1598–1618. doi: 10.1166/jbn.2017.2475
115
RayS.LiZ.HsuC. H.HwangL. P.LinY. C.ChouP. T.et al. (2018). Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics. Theranostics8, 6322–6349. doi: 10.7150/thno.27828
116
RicciutiB.LeonardiG. C.PuccettiP.FallarinoF.BianconiV.SahebkarA.et al. (2019). Targeting indoleamine-2,3-dioxygenase in cancer: scientific rationale and clinical evidence. Pharmacol. Ther.196, 105–116. doi: 10.1016/j.pharmthera.2018.12.004
117
RielyG. J.JohnsonM. L.MedinaC.RizviN. A.MillerV. A.KrisM. G.et al. (2011). A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J. Thorac. Oncol.6, 1435–1437. doi: 10.1097/JTO.0b013e318223c099
118
RingsdorfH. (2010). Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp.51, 135–153. doi: 10.1002/polc.5070510111
119
SafariE.GhorghanluS.Ahmadi-KhiaviH.MehranfarS.RezaeiR.MotallebnezhadM. (2019). Myeloid-derived suppressor cells and tumor: current knowledge and future perspectives. J. Cell. Physiol.234, 9966–9981. doi: 10.1002/jcp.27923
120
SaitoG.SwansonJ. A.LeeK. D. (2003). Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev.55, 199–215. doi: 10.1016/S0169-409X(02)00179-5
121
ShankarS.GanapathyS.SrivastavaR. K. (2007). Green tea polyphenols: biology and therapeutic implications in cancer. Front. Biosci.12, 4881–4899. doi: 10.2741/2435
122
ShiJ.KantoffP. W.WoosterR.FarokhzadO. C. (2016). Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer17, 20. doi: 10.1038/nrc.2016.108
123
SiegelR. L.MillerK. D.JemalA. (2017). Cancer Statistics, 2017. CA Cancer J. Clin.67, 7–30. doi: 10.3322/caac.21387
124
SiegelinM. D.HabelA.GaiserT. (2008). Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. Neurosci. Lett.448, 161–165. doi: 10.1016/j.neulet.2008.10.036
125
SimanshuD. K.NissleyD. V.MccormickF. (2017). RAS proteins and their regulators in human disease. Cell170, 17–33. doi: 10.1016/j.cell.2017.06.009
126
SinglaA. K.GargA.AggarwalD. (2002). Paclitaxel and its formulations. Int. J. Pharm.235, 179–192. doi: 10.1016/S0378-5173(01)00986-3
127
SmithR. A.AndrewsK. S.BrooksD.FedewaS. A.Manassaram-BaptisteD.SaslowD.et al. (2017). Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin.67, 100–121. doi: 10.3322/caac.21392
128
SolimanH.Mediavilla-VarelaM.AntoniaS. (2010). Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J.16, 354–359. doi: 10.1097/PPO.0b013e3181eb3343
129
SongX.DuJ.ZhaoW.GuoZ. (2017). Epigallocatechin-3-gallate(EGCG): mechanisms and the combined applications. Comb. Chem. High Throughput Screen.20, 872–885. doi: 10.2174/1386207321666171218115850
130
SukJ. S.XuQ.KimN.HanesJ.EnsignL. M. (2016). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev.99, 28–51. doi: 10.1016/j.addr.2015.09.012
131
SunM.WangK.OupickyD. (2018a). Advances in stimulus-responsive polymeric materials for systemic delivery of nucleic acids. Adv. Healthc. Mater.7, 1701070. doi: 10.1002/adhm.201701070
132
SunN.ZhaoC.ChengR.LiuZ.LiX.LuA.et al. (2018b). Cargo-free nanomedicine with pH sensitivity for codelivery of DOX conjugated prodrug with SN38 to synergistically eradicate breast cancer stem cells. Mol. Pharm.15, 3343–3355. doi: 10.1021/acs.molpharmaceut.8b00367
133
TanS.ZouC.ZhangW.YinM.GaoX.TangQ. (2017). Recent developments in d-alpha-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy. Drug Deliv.24, 1831–1842. doi: 10.1080/10717544.2017.1406561
134
TanbourR.MartinsA. M.PittW. G.HusseiniG. A. (2016). Drug delivery systems based on polymeric micelles and ultrasound: a review. Curr. Pharm. Des.22, 2796–2807. doi: 10.2174/1381612822666160217125215
135
TaurinS.NehoffH.GreishK. (2012). Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control. Release164, 265–275. doi: 10.1016/j.jconrel.2012.07.013
136
TorreL. A.IslamiF.SiegelR. L.WardE. M.JemalA. (2017). Global cancer in women: burden and trends. Cancer Epidemiol. Biomarkers Prev.26, 444–457. doi: 10.1158/1055-9965.EPI-16-0858
137
TuS. H.KuC. Y.HoC. T.ChenC. S.HuangC. S.LeeC. H.et al. (2011). Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced alpha9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol. Nutr. Food Res.55, 455–466. doi: 10.1002/mnfr.201000254
138
UlbrichK.SubrV. (2004). Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev.56, 1023–1050. doi: 10.1016/j.addr.2003.10.040
139
UyttenhoveC.PilotteL.TheateI.StroobantV.ColauD.ParmentierN.et al. (2003). Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.9, 1269–1274. doi: 10.1038/nm934
140
Van HoorenL.GeorganakiM.HuangH.MangsboS. M.DimbergA. (2016). Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget7, 50277–50289. doi: 10.18632/oncotarget.10364
141
VannemanM.DranoffG. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer12, 237–251. doi: 10.1038/nrc3237
142
WangJ.LiS.HanY.GuanJ.ChungS.WangC.et al. (2018a). Poly(ethylene glycol)-polylactide micelles for cancer therapy. Front. Pharmacol.9, 202. doi: 10.3389/fphar.2018.00202
143
WangJ.SunJ.ChenQ.GaoY.LiL.LiH.et al. (2012). Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials33, 6877–6888. doi: 10.1016/j.biomaterials.2012.06.019
144
WangY. Q.LuJ. L.LiangY. R.LiQ. S. (2018b). Suppressive effects of EGCG on cervical cancer. Molecules23, E2334. doi: 10.3390/molecules23092334
145
WaniM. C.TaylorH. L.WallM. E.CoggonP.McphailA. T. (1971). Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc.93, 2325–2327. doi: 10.1021/ja00738a045
146
WickiA.WitzigmannD.BalasubramanianV.HuwylerJ. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Release200, 138–157. doi: 10.1016/j.jconrel.2014.12.030
147
XuJ.ZhangX.ChenY.HuangY.WangP.WeiY.et al. (2017). Improved micellar formulation for enhanced delivery for paclitaxel. Mol. Pharm.14, 31–41. doi: 10.1021/acs.molpharmaceut.6b00581
148
YangC.WuT.QiY.ZhangZ. (2018a). Recent advances in the application of vitamin E TPGS for drug delivery. Theranostics8, 464–485. doi: 10.7150/thno.22711
149
YangT.LanY.CaoM.MaX.CaoA.SunY.et al. (2018b). Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer. Colloids Surf. B Biointerfaces175, 106–115. doi: 10.1016/j.colsurfb.2018.11.082
150
YangT.LiF.ZhangH.FanL.QiaoY.TanG.et al. (2015). Multifunctional pH-sensitive micelles for tumor-specific uptake and cellular delivery. Polym. Chem.6, 1373–1382. doi: 10.1039/C4PY01403K
151
YaoY. F.LiuX.LiW. J.ShiZ. W.YanY. X.WangL. F.et al. (2017). (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice. Life Sci.180, 151–159. doi: 10.1016/j.lfs.2016.12.004
152
YinW.KeW.ChenW.XiL.ZhouQ.MukerabigwiJ. F.et al. (2019). Integrated block copolymer prodrug nanoparticles for combination of tumor oxidative stress amplification and ROS-responsive drug release. Biomaterials195, 63–74. doi: 10.1016/j.biomaterials.2018.12.032
153
YooH. S.ParkT. G. (2004a). Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Control. Release100, 247–256. doi: 10.1016/j.jconrel.2004.08.017
154
YooH. S.ParkT. G. (2004b). Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release96, 273–283. doi: 10.1016/j.jconrel.2004.02.003
155
YoukH. J.LeeE.ChoiM. K.LeeY. J.ChungJ. H.KimS. H.et al. (2005). Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J. Control. Release107, 43–52. doi: 10.1016/j.jconrel.2005.05.014
156
YounY. S.BaeY. H. (2018). Perspectives on the past, present, and future of cancer nanomedicine. Adv. Drug Deliv. Rev.130, 3–11. doi: 10.1016/j.addr.2018.05.008
157
ZamanakouM.GermenisA. E.KaranikasV. (2007). Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol. Lett.111, 69–75. doi: 10.1016/j.imlet.2007.06.001
158
ZhaiQ.ChenY.XuJ.HuangY.SunJ.LiuY.et al. (2017). Lymphoma immunochemotherapy: targeted delivery of doxorubicin via a dual functional nanocarrier. Mol. Pharm.14, 3888–3895. doi: 10.1021/acs.molpharmaceut.7b00606
159
ZhangY.ZhuoR. X. (2005). Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly (ethylene glycol) and polycaprolactone. Biomaterials26, 6736–6742. doi: 10.1016/j.biomaterials.2005.03.045
160
ZhangG.LiX.LiaoQ.LiuY.XiK.HuangW.et al. (2018a). Water-dispersible PEG-curcumin/amine-functionalized covalent organic framework nanocomposites as smart carriers for in vivo drug delivery. Nat. Commun.9, 2785. doi: 10.1038/s41467-018-04910-5
161
ZhangK.TangX.ZhangJ.LuW.LinX.ZhangY.et al. (2014a). PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications. J. Control. Release183, 77–86. doi: 10.1016/j.jconrel.2014.03.026
162
ZhangP.LuJ.HuangY.ZhaoW.ZhangY.ZhangX.et al. (2014b). Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. AAPS J.16, 114–124. doi: 10.1208/s12248-013-9536-9
163
ZhangP.WuJ.XiaoF.ZhaoD.LuanY. (2018b). Disulfide bond based polymeric drug carriers for cancer chemotherapy and relevant redox environments in mammals. Med. Res. Rev.38, 1485–1510. doi: 10.1002/med.21485
164
ZhangX.ChenD.BaS.ZhuJ.ZhangJ.HongW.et al. (2014c). Poly(l-histidine) based triblock copolymers: pH induced reassembly of copolymer micelles and mechanism underlying endolysosomal escape for intracellular delivery. Biomacromolecules15, 4032–4045. doi: 10.1021/bm5010756
165
ZhangX.HuangY.LiS. (2014d). Nanomicellar carriers for targeted delivery of anticancer agents. Ther. Deliv.5, 53–68. doi: 10.4155/tde.13.135
166
ZhangX.HuangY.ZhaoW.ChenY.ZhangP.LiJ.et al. (2014e). PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel. Mol. Pharm.11, 2807–2814. doi: 10.1021/mp500181x
167
ZhangX.HuangY.ZhaoW.LiuH.MarquezR.LuJ.et al. (2014f). Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif. Biomacromolecules15, 4326–4335. doi: 10.1021/bm501339j
168
ZhangX.LiuK.HuangY.XuJ.LiJ.MaX.et al. (2014g). Reduction-sensitive dual functional nanomicelles for improved delivery of paclitaxel. Bioconjug. Chem.25, 1689–1696. doi: 10.1021/bc500292j
169
ZhangX.LuJ.HuangY.ZhaoW.ChenY.LiJ.et al. (2013). PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug. Chem.24, 464–472. doi: 10.1021/bc300608h
170
ZhangY.HuangY.LiS. (2014h). Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech15, 862–871. doi: 10.1208/s12249-014-0113-z
171
ZhangY.HuangY.ZhaoW.LuJ.ZhangP.ZhangX.et al. (2014i). Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity. AAPS J.16, 1282–1291. doi: 10.1208/s12248-014-9651-2
172
ZhangZ.TanS.FengS. S. (2012). Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials33, 4889–4906. doi: 10.1016/j.biomaterials.2012.03.046
173
ZhaoD.LiuN.ShiK.WangX.WuG. (2015). Preparation of a multifunctional verapamil-loaded nano-carrier based on a self-assembling PEGylated prodrug. Colloids Surf. B Biointerfaces135, 682–688. doi: 10.1016/j.colsurfb.2015.08.018
174
ZhaoM.HuangY.ChenY.XuJ.LiS.GuoX. (2016). PEG-Fmoc-ibuprofen conjugate as a dual functional nanomicellar carrier for paclitaxel. Bioconjug. Chem.27, 2198–2205. doi: 10.1021/acs.bioconjchem.6b00415
175
ZhouQ.ZhangL.YangT.WuH. (2018a). Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int. J. Nanomed.13, 2921–2942. doi: 10.2147/IJN.S158696
176
ZhouY.YuF.ZhangF.ChenG.WangK.SunM.et al. (2018b). Cyclam-modified PEI for combined VEGF siRNA silencing and CXCR4 inhibition to treat metastatic breast cancer. Biomacromolecules19, 392–401. doi: 10.1021/acs.biomac.7b01487
177
ZhuM. M. T.DancsokA. R.NielsenT. O. (2019). Indoleamine dioxygenase inhibitors: clinical rationale and current development. Curr. Oncol. Rep.21, 2. doi: 10.1007/s11912-019-0750-1
178
ZuninoF.PratesiG. (2004). Camptothecins in clinical development. Expert Opin. Investig. Drugs13, 269–284. doi: 10.1517/13543784.13.3.269
Summary
Keywords
polyethylene glycol (PEG), dual-functional nanomicelles, cancer therapy, multidrug resistance, drug loading capacity, cancer immunochemotherapy
Citation
Li Y, Zhang T, Liu Q and He J (2019) PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy. Front. Pharmacol. 10:808. doi: 10.3389/fphar.2019.00808
Received
16 April 2019
Accepted
24 June 2019
Published
19 July 2019
Volume
10 - 2019
Edited by
Ali H. Eid, American University of Beirut, Lebanon
Reviewed by
Baolin Guo, Xi’an Jiaotong University, China; Song Li, University of Pittsburgh, United States
Updates
Copyright
© 2019 Li, Zhang, Liu and He.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jinhan He, jinhanhe@scu.edu.cn
This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.